DDInter458 DDInter1387
Cyclosporine is a calcineurin inhibitor known for its immunomodulatory properties that prevent organ transplant rejection and treat various inflammatory and autoimmune conditions. It is isolated from the fungus _Beauveria nivea_. Initially manufactured by Sandoz and approved for use by the FDA in 1983, cyclosporine is now available in various products by Novartis (previously known as Sandoz).[L11097,L3734,L11118]
Panobinostat is an oral deacetylace (DAC) inhibitor approved on February 23, 2015 by the FDA for the treatment of multiple myeloma. The approval was accelerated based on progression-free survival, therefore confirmatory trials by the sponsor to demonstrate clinical efficacy in multiple myeloma treatment are in progress of being conducted. Panobinostat is marketed by Novartis under the brand name Farydak. Panobinostat acts as a non-selective histone deacetylase inhibitor (pan-HDAC inhibitor) and it is the most potent DAC inhibiting agent available on the market.
Cyclosporine {u} (Compound) binds {v} (Gene) CYP2C8
CYP2C8 {u} (Gene) is bound by {v} (Compound) Sulfamethoxazole
Sulfamethoxazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Panobinostat
Cyclosporine {u} (Compound) binds {v} (Gene) CYP2C8
CYP2C8 {u} (Gene) is bound by {v} (Compound) Nifedipine
Nifedipine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Panobinostat
Cyclosporine {u} (Compound) upregulates {v} (Gene) SLC1A4
SLC1A4 {u} (Gene) is upregulated by {v} (Compound) Sulfamethoxazole
Sulfamethoxazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Panobinostat
Cyclosporine {u} (Compound) downregulates {v} (Gene) PCNA
PCNA {u} (Gene) is downregulated by {v} (Compound) Sulfamethoxazole
Sulfamethoxazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Panobinostat
Cyclosporine {u} (Compound) upregulates {v} (Gene) SLC1A4
SLC1A4 {u} (Gene) is upregulated by {v} (Compound) Dabrafenib
Dabrafenib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Panobinostat
Cyclosporine {u} (Compound) causes {v} (Side Effect) Purpura
Purpura {u} (Side Effect) is caused by {v} (Compound) Sulfamethoxazole
Sulfamethoxazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Panobinostat
Cyclosporine {u} (Compound) downregulates {v} (Gene) PCNA
PCNA {u} (Gene) is downregulated by {v} (Compound) Salmeterol
Salmeterol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Panobinostat
Cyclosporine {u} (Compound) upregulates {v} (Gene) SLC1A4
SLC1A4 {u} (Gene) is upregulated by {v} (Compound) Clofarabine
Clofarabine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Panobinostat
Cyclosporine {u} (Compound) causes {v} (Side Effect) Purpura
Purpura {u} (Side Effect) is caused by {v} (Compound) Nifedipine
Nifedipine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Panobinostat
Cyclosporine {u} (Compound) downregulates {v} (Gene) PCNA
PCNA {u} (Gene) is downregulated by {v} (Compound) Dabrafenib
Dabrafenib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Panobinostat
Cyclosporine (Compound) binds CYP2C8 (Gene) and CYP2C8 (Gene) is bound by Sulfamethoxazole (Compound) and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Panobinostat
Cyclosporine (Compound) binds CYP2C8 (Gene) and CYP2C8 (Gene) is bound by Nifedipine (Compound) and Nifedipine may cause a moderate interaction that could exacerbate diseases when taken with Panobinostat
Cyclosporine (Compound) upregulates SLC1A4 (Gene) and SLC1A4 (Gene) is upregulated by Sulfamethoxazole (Compound) and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Panobinostat
Cyclosporine (Compound) downregulates PCNA (Gene) and PCNA (Gene) is downregulated by Sulfamethoxazole (Compound) and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Panobinostat
Cyclosporine (Compound) upregulates SLC1A4 (Gene) and SLC1A4 (Gene) is upregulated by Dabrafenib (Compound) and Dabrafenib may cause a moderate interaction that could exacerbate diseases when taken with Panobinostat
Cyclosporine (Compound) causes Purpura (Side Effect) and Purpura (Side Effect) is caused by Sulfamethoxazole (Compound) and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Panobinostat
Cyclosporine (Compound) downregulates PCNA (Gene) and PCNA (Gene) is downregulated by Salmeterol (Compound) and Salmeterol may cause a moderate interaction that could exacerbate diseases when taken with Panobinostat
Cyclosporine (Compound) upregulates SLC1A4 (Gene) and SLC1A4 (Gene) is upregulated by Clofarabine (Compound) and Clofarabine may cause a moderate interaction that could exacerbate diseases when taken with Panobinostat
Cyclosporine (Compound) causes Purpura (Side Effect) and Purpura (Side Effect) is caused by Nifedipine (Compound) and Nifedipine may cause a moderate interaction that could exacerbate diseases when taken with Panobinostat
Cyclosporine (Compound) downregulates PCNA (Gene) and PCNA (Gene) is downregulated by Dabrafenib (Compound) and Dabrafenib may cause a moderate interaction that could exacerbate diseases when taken with Panobinostat